- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.10. | Sanofi moves ahead with CD&R deal for stake in consumer business | ||
| 21.10. | Oral version of Novo diabetes drug protects heart health in large study | ||
| 21.10. | Brain drug developer Seaport raises another $225M | ||
| 21.10. | PureTech thinks the "hub-and-spoke" startup model is still a good bet. If only investors agreed. | ||
| 21.10. | Pharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology | ||
| 21.10. | Harnessing the power of upstream platform integration to accelerate biopharma innovation | ||
| 18.10. | Merck antibody reduces RSV-related disease, hospitalizations in trial | ||
| 18.10. | Gilead withdraws Trodelvy in bladder cancer | ||
| 18.10. | CVS replaces CEO Karen Lynch with Caremark head | ||
| 18.10. | PTC rebuffed again by EMA; Novartis licenses China-based biotech's cancer drug | ||
| 17.10. | Sage to cut one-third of workforce, streamline drug pipeline | ||
| 17.10. | After rejections, AbbVie secures approval for Parkinson's drug | ||
| 17.10. | Sanofi, expanding in radiopharma, strikes a joint venture deal | ||
| 17.10. | Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe | ||
| 16.10. | Novocure wins FDA approval for electric field device in lung cancer | ||
| 16.10. | FDA puts Novavax flu vaccine trials on hold | ||
| 16.10. | Wave sees RNA editing validation in early trial results | ||
| 16.10. | GSK sues Moderna for infringing mRNA vaccine patents | ||
| 15.10. | Forbion follows string of startup exits with $2.2B fundraise | ||
| 15.10. | Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss | ||
| 15.10. | Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data | ||
| 15.10. | As election day nears, Trump and Harris veer in different directions on pharma | ||
| 14.10. | FDA, facing pressure, to review position on Zepbound, Mounjaro shortage | ||
| 14.10. | Lundbeck to buy brain drug developer Longboard for $2.6B | ||
| 14.10. | GSK says antibody drug succeeds in testing for chronic nasal condition |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
